Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Eun Young Kang(University of Calgary), P. Mackenzie(Royal Hospital for Women), Michelle da Cunha Torres(The University of Melbourne), Weiva Sieh(The University of Texas MD Anderson Cancer Center), Constantina Mateoiu(University of Gothenburg), Nirmala Pandeya(University of Queensland), Linda S. Cook, Ellen L. Goode(Mayo Clinic in Arizona), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Peter A. Fasching(Universitätsklinikum Erlangen), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Prue E. Allan(Epworth Hospital), Dorota M. Gertig(The University of Melbourne), Linda E. Kelemen(Medical University of South Carolina), Anna DeFazio(The University of Sydney), Michael E. Jones(Institute of Cancer Research), David D.L. Bowtell(The University of Melbourne), Michael S. Anglesio(University of British Columbia), Suzanne Moore(The University of Sydney), Marc T. Goodman(Cedars-Sinai Medical Center), T. Sadkowsky(QIMR Berghofer Medical Research Institute), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Zhongyue Xing(The University of Melbourne), Catherine J. Kennedy(The University of Sydney), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Cécile Le Page(Institut Universitaire en Santé Mentale de Québec), R. Paul Robertson(University of Washington), Suha Deen(Nottingham University Hospitals NHS Trust), Sián Fereday(Peter MacCallum Cancer Centre), M. Malt(QIMR Berghofer Medical Research Institute), Dane Cheasley(The University of Melbourne), Karin Sundfeldt(Sahlgrenska University Hospital), A. Mellon(Hunter New England Local Health District), Simone M. Rowley(Victorian Clinical Genetics Services), Kurosh Rahimi(Centre Hospitalier de l’Université de Montréal), Jennifer A. Doherty(Cancer Prevention Institute of California), A. Green(QIMR Berghofer Medical Research Institute), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Carolina Salazar(Peter MacCallum Cancer Centre), Nadia Traficante(The University of Melbourne), Nhu D. Le(BC Cancer Agency), K.R. Harrap(QIMR Berghofer Medical Research Institute), C. Blake Gilks(Fox Chase Cancer Center), T. Vanden Bergh(Royal Hospital for Women), Jillian A. Hung(Millennium Institute), David G. Huntsman(University of British Columbia), Matthew J. Wakefield(The University of Melbourne)
Cited by 43
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k